‘The US has begun late stage clinical trials into a drug formulated to fight Covid-19, officials said Tuesday. The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada’s Abcellera Biologics. It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera. The Phase 3 trial will initially enrol some 300 volunteers around the world who have been hospitalised with mild to moderate Covid-19 with fewer than 13 days of symptoms.’
Read here (South China Morning Post, August 4, 2020)
